Aim: To analyse the self-reported degree of and factors influencing the compliance to desferrioxamine (DFO) therapy in children with transfusion-dependent thalassaemia major in Malaysia. Methods: A cross-sectional study was conducted on all children with thalassaemia major on DFO attending Likas Hospital, Sabah, in September 2008. Patients or carer-providers were interviewed to report on the degree of compliance as either highly (administering >90 of DFO), moderately (51-90), poorly (1-50) or non-compliant (0) to DFO in the preceding month. The latest serum ferritin levels were noted. Results: The median (range) age at first blood transfusion of these 139 (73 males, median (range) age at interview: 9.0 years (2-16 years)) patients were 1.0 ...
Children with thalassemia major must be treated with life-long blood transfusions. Evidence suggests...
Background: Patients with transfusion-dependent thalassemia (TDT) risk iron overload and require iro...
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to i...
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine t...
Background: Thalassemia is a chronic disease requiring lifelong treatment. The adherence to regular ...
Introduction: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM...
Introduction: Deferasirox, an oral iron chelator has been proved to be very safe and effective in be...
BACKGROUND:Management of thalassemia major requires patients to have life-long access to a treatment...
Long-term survival in beta-thalassaemia major is strongly influenced by adherence to iron chelation ...
ABSTRACT: RELATIONSHIP OF COMPLIANCE WITH KELSI THERAPY WITH SERUM FERITIN LEVELS IN THALASSEMIA β M...
Background Iron overload is a major problem in patients with major thalassemia. An effective and saf...
Objective: This study was conducted to identify predictors of non-adherence to iron chelation therap...
Objective: beta-thalassemia is a widespread disease. Long term transfusion is the most important the...
Children with thalassemia major must be treated with life-long blood transfusions. Evidence suggests...
AbstractObjectiveDescribe our experience with combination therapy of Deferiprone (DFP) and Desferrio...
Children with thalassemia major must be treated with life-long blood transfusions. Evidence suggests...
Background: Patients with transfusion-dependent thalassemia (TDT) risk iron overload and require iro...
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to i...
Background and Aim: With the introduction of long term subcutaneous administration of Deferoxamine t...
Background: Thalassemia is a chronic disease requiring lifelong treatment. The adherence to regular ...
Introduction: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM...
Introduction: Deferasirox, an oral iron chelator has been proved to be very safe and effective in be...
BACKGROUND:Management of thalassemia major requires patients to have life-long access to a treatment...
Long-term survival in beta-thalassaemia major is strongly influenced by adherence to iron chelation ...
ABSTRACT: RELATIONSHIP OF COMPLIANCE WITH KELSI THERAPY WITH SERUM FERITIN LEVELS IN THALASSEMIA β M...
Background Iron overload is a major problem in patients with major thalassemia. An effective and saf...
Objective: This study was conducted to identify predictors of non-adherence to iron chelation therap...
Objective: beta-thalassemia is a widespread disease. Long term transfusion is the most important the...
Children with thalassemia major must be treated with life-long blood transfusions. Evidence suggests...
AbstractObjectiveDescribe our experience with combination therapy of Deferiprone (DFP) and Desferrio...
Children with thalassemia major must be treated with life-long blood transfusions. Evidence suggests...
Background: Patients with transfusion-dependent thalassemia (TDT) risk iron overload and require iro...
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to i...